| gap-pubmed-20260410- | How does cdk5's role in pain processing mechanistically relate to its neurodegen | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What structural features determine cdk5-tau interaction specificity beyond the A | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Can CHCHD6 compensation strategies translate therapeutically to human AD given s | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of APP intracellular domain binding to the CHCHD | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does neuronal cholesterol accumulation mechanistically promote amyloid patho | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What triggers irreversible SERCA2 Cys oxidation in the context of vascular calci | open | 0.81 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does SERCA2-TSPO-MCU coupling at MAMs specifically drive osteogenic transdif | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the minimum effective duration and dose of quercetin treatment for susta | open | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does quercetin's neuroprotection depend on direct antioxidant activity or indire | resolved | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which quercetin crosses the blood- | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What triggers pT217-tau aggregation on microtubules during early dendritic degen | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does pT217-tau gain access from synaptic sites to cerebrospinal fluid and pl | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms drive pT217-tau trafficking between excitatory neurons | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | Can resveratrol or other sirtuin activators prevent or slow neurodegeneration in | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link sirtuin activation to neuroprotection in human ne | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do mAbs targeting mid-region versus other tau epitopes show differential the | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What specific factors determine efficacy versus side effects in anti-Aβ monoclon | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What triggers the compensatory activation of monoenzymatic neurons in neurodegen | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do serotoninergic neurons initiate dopamine synthesis when they lack native | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable L-DOPA transfer between monoenzymatic TH-neuron | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do subfield-specific anomalies in CA1 and dentate gyrus contribute to distin | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What mechanisms link neuroinflammation and microglial activation to hippocampal | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do genetic mutations in Shank3, Syngap1, Fmr1, and Nlgn3 specifically disrup | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What principles guide optimal combination of autophagy modulators with epigeneti | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do epigenetic and post-translational modifications mechanistically control a | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether autophagy is cytoprotective versus detrimental in neurod | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does β-catenin signaling mechanistically drive myofibroblast activation in o | open | 0.79 | 0.00 | 2026-04-10 | 0 | | fibrosis |
| gap-pubmed-20260410- | What mechanisms explain how β-catenin mutations can be both oncogenic and tumor | open | 0.80 | 0.00 | 2026-04-10 | 0 | | cancer-biology |
| gap-pubmed-20260410- | What determines individual resilience versus vulnerability to memory decline wit | open | 0.85 | 0.00 | 2026-04-10 | 0 | | cognitive-resilience |
| gap-pubmed-20260410- | How does HDAC4 regulate the observed protein changes in both normal aging and AD | open | 0.83 | 0.00 | 2026-04-10 | 0 | | epigenetic-regulation |
| gap-pubmed-20260410- | What mechanisms underlie the 36 shared protein changes between normal aging and | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the causal relationship between sleep deprivation-induced gene expressio | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do the identified hub genes mechanistically link sleep deprivation to cognit | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | sleep-neuroscience |
| gap-pubmed-20260410- | How does SorLA deficiency protect cholinergic neurons from NGF withdrawal-induce | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the downstream pathways by which SorLA regulates tau phosphorylation in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does SorLA simultaneously exacerbate amyloid pathology while protecting agai | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How can comparative analysis across multiple ALS models be systematically integr | resolved | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain the discrepancies in ALS pathological pathways across di | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the mechanistic connection between OA's effects on GDF11/ErbB4/TrkB sign | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does OA simultaneously regulate multiple independent cellular pathways (auto | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do intralesional bacteria directly cause retinal neurodegeneration in CRB1-m | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does colonic CRB1 restoration rescue retinal degeneration without repairing | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms enable gut bacteria to translocate specifically to the | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does aripiprazole's partial agonist activity at DRD2 confer its unique thera | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms underlie the emergence of tardive dyskinesia and extrapyramidal | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What structural mechanisms govern complement receptor cross-talk between innate | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do complement receptor structural features mechanistically drive neuroinflam | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the optimal dosing regimens and treatment duration for metformin as a n | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific mechanisms by which metformin prevents neurodegeneration b | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the temporal relationship between Aβ-induced TLR4/NF-κB activation and c | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |